Does carvedilol induce biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility?
Carvedilol promotes cardiac inotropy through a novel β1AR-NOS3 signalling pathway, suggesting a potential therapeutic target for heart failure with reduced ejection fraction.
These observations present a novel β1AR-NOS3 signalling pathway to promote cardiac inotropy in the heart, indicating that this signalling paradigm may be targeted in therapy of heart diseases with reduced ejection fraction.
Wang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: